This research is devoted to solving an environmental problem, cleaning of the Kazakhstan air basin, through treatment of auto-transport toxic exhaust by improving the hydrocarbon composition of motor fuels and neutralizing exhaust gas toxic components. The catalytic hydrodearomatization of gasoline fractions (from the reforming stage) of the Atyrau and Pavlodar Refineries and the neutralization of exhaust gas toxic components from an internal combustion engine (ICE) were studied. Two hydrotreated gasoline fractions were tested during ICE operation. The research shows that 100% benzene conversion is observed over Rh-Pt(9:1)/γ-Al₂O₃ catalysts; that is, benzene is completely removed from both fractions, and the aromatics content decreases from 56.24–58.12% to 21.29–21.89%, within the values of the Euro-5,6 standard. Catalytic treatment of fuels reduces fuel consumption of the ICE engine by 2–3% compared to the initial gasoline fractions, the CO content in the exhaust gases decreases by 6.6–16.2%, and the hydrocarbon content decreases by 7.8–24.7%. In order to neutralize the ICE exhaust gas toxic components, the catalyst 10% Co + 0.5% Pt/Al₂O₃ was used, with which the CO conversion reaches 100% and the hydrocarbon conversion 94.2% and 91.5% for both gasoline fractions. The catalysts were characterized by electron microscopy (EM), X-ray diffraction (XRD), Brunauer–Emmett–Teller (BET), thermoprogrammed desorption (TPD) and thermoprogrammed reduction (TPR) methods. It was shown by the TPD and EM methods that at the addition of Pt to the Rh-catalyst, the formation of mixed bimetallic Rh-Pt-agglomerates occurs, and hydrogen appears in the TPD spectrum, adsorbed in the form of a new single peak uncharacteristic for the Rh-catalyst. This leads to high activity and selectivity in the hydrogenation of benzene and aromatic compounds in the gasoline fractions. The XRD and TPR results show the formation of CoAl₂O₄ spinels, on which inactive oxygen is formed for the oxidation of CO and hydrocarbons. Modification of the catalyst by Pt and Mg prevents spinel formation, thereby increasing the activity of the catalysts.

In Central Eurasia, the availability of drugs that are inhibitors of the SARS-CoV-2 virus and have proven clinical efficacy is still limited. The aim of this study was to evaluate the activity of drugs that were available in Kazakhstan during the acute phase of the epidemic against SARS-CoV-2. Antiviral activity is reported for Favipiravir, Tilorone, and Cridanimod, which are registered drugs used for the treatment of respiratory viral infections in Kazakhstan. A licorice (Glycyrrhiza glabra) extract was also incorporated into this study because it offered an opportunity to develop plant-derived antivirals. The Favipiravir drug, which had been advertised in local markets as an anti-COVID cure, showed no activity against SARS-CoV-2 in cell cultures. On the contrary, Cridanimod showed impressive high activity (median inhibitory concentration 66 μg/mL) against SARS-CoV-2, justifying further studies of Cridanimod in clinical trials. Tilorone, despite being in the same pharmacological group as Cridanimod, stimulated SARS-CoV-2 replication in cultures. The licorice extract inhibited SARS-CoV-2 replication in cultures, with a high median effective concentration of 16.86 mg/mL. Conclusions: The synthetic, low-molecular-weight compound Cridanimod suppresses SARS-CoV-2 replication at notably low concentrations, and this drug is not toxic to cells at therapeutic concentrations. In contrast to its role as an inducer of interferons, Cridanimod is active in cells that have a genetic defect in interferon production, suggesting a different mechanism of action. Cridanimod is an attractive drug for inclusion in clinical trials against SARS-CoV-2 and, presumably, other coronaviruses. The extract from licorice shows low activity against SARS-CoV-2. At the same time, high doses of 2 g/kg of this plant extract show little or no acute toxicity in animal studies; for this reason, licorice products can still be considered for further development as a safe, orally administered adjunctive therapy.

Oriental Journal of Chemistry is a peer reviewed quarterly research journal of pure and applied chemistry. It publishes standard research papers in almost all thrust areas of current chemistry of academic and commercial importance. It provides a platform for rapid publication of quality research papers, reviews and chemistry letters. Oriental Journal of Chemistry is abstracted and indexed in almost all reputed National and International agencies.